New strategies in controlling drug resistance in chronic myeloid leukemia

American Journal of Health-System Pharmacy

Volumn 64, Issue 24 SUPPL., 2007, Pages

  Frame, David ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antineoplastic agents; Blood levels; Dosage; Economics; Imatinib mesylate; Leukemia; Mechanism of action; Mortality; Oasatinib; Pharmacokinetics; Quality of life; Resistance; Toxicity; Transplantation

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ECONOMICS; GENE AMPLIFICATION; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

EID: 37349051416     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070483     Document Type: Conference Paper

References (19)

1. Picard S, Titier K, Etienne G et al. Trough plasma imatinib concentrations are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. ASH Annual Meeting Abstracts. 2006; 108:2141.
2. Larson RA, Druker BJ, Guilhot F et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data. ASH Annual Meeting Abstracts. 2006; 108:429.
3. Cortes J, Giles F, Salvado AJ et al. Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group. ASH Annual Meeting Abstracts. 2006; 108:2149.
4. Aoki T, Kantarjian H, O'Brien S et al. High-dose (hd) imatinib provides better responses in patients with untreated early chronic phase (CP) CML. ASH Annual Meeting Abstracts. 2006; 108:2143.
5. Rosti G, Castagnetti F, Amabile M et al. Imatinib high dose (800 mg): results of a phase II trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell'Adulto) CML working party in intermediate Sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high Sokal risk patients. ASH Annual Meeting Abstracts. 2006; 108:4776.
6. Sokal JE, Baccarani M, Russo D et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988; 25:49-61.
7. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003; 101:473-5.
8. Warmuth M, Danhauser-Riedl S, Hallek M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol. 1999; 78:49-64.
9. Targeting tumor invasion: evaluating selective, dual-specific Scr/Abl kinase inhibition. www.cancerline.com/cancerlinehcp/15602_18503_0_0_0.aspx?mid= (accessed 2007 Sept 10).
10. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354:2531-41.
11. Baccarani M, Kantarjian HM, Apperley JF et al. Efficacy of dasatinib (SPRYCEL[R]) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 START-C phase II study. ASH Annual Meeting Abstracts. 2006; 108:164.
12. Shah N, Pasquini R, Rousselot P et al. Dasatinib (SPRYCEL[R]) vs escalated dose of imatinib (im) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib: results of the CA180-017 START-R randomized study. ASH Annual Meeting Abstracts. 2006; 108:167.
13. Hochhaus A, Kim DW, Rousselot P et al. Dasatinib (SPRYCEL[R]) 50 mg or 70 mg BID versus 100 mg or 140 mg QD in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to imatinib: results of the CA180-034 study. ASH Annual Meeting Abstracts. 2006; 108:166.
14. Hehlmann R, Pfirrmann M, Hochhaus A et al. Randomized comparison of primary allogeneic stem cell transplantation and best available drug treatment in chronic myeloid leukemia. ASH Annual Meeting Abstracts. 2006; 108:427.
15. Mahon F-X, Huguet F, Etienne G et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission: an update follow-up. ASH Annual Meeting Abstracts. 2006; 108:2154.
16. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006; 12:570-7.
17. Warren E, Ward S, Gordois A et al. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther. 2004; 26:1924-33.
18. Reed SD, Anstrom KJ, Ludmer JA et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004; 101:2574-83.
19. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005; 25:325-34.